Bio News

BeiGene’s Brukinsa demonstrated superiority in progression-free survival (PFS) in a phase 3 trial of first-line mantle cell lymphoma. BeiGene evaluated Brukinsa plus rituximab versus bendamustine plus rituximab. BeiGene reported second-quarter Brukinsa sales of $1.2 billion, up 31% from the previous year, or approximately 1.7064 trillion won.

BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882